Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation

SIMPLE SUMMARY: Metastatic renal cell carcinoma continues to have a poor prognosis. Chemotherapies and immuno-oncologic therapies have garnered increasing importance in cancer therapy, with improvements in patient care and survival. However, a large proportion of patients present with tumors resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenberg, Jacob W., Kim, Hogyoung, Ahn, Miae, Moustafa, Ahmed A., Zhou, He, Barata, Pedro C., Boulares, A. Hamid, Abdel-Mageed, Asim B., Krane, Louis S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870174/
https://www.ncbi.nlm.nih.gov/pubmed/35205655
http://dx.doi.org/10.3390/cancers14040903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870174/
https://www.ncbi.nlm.nih.gov/pubmed/35205655
http://dx.doi.org/10.3390/cancers14040903

Ejemplares similares